Latest Pharmaceutical Companies News

Osteopore Limited has secured an exclusive multi-year distribution agreement with Majeton to commercialise its dental and maxillofacial products in China, Hong Kong, and Macau, marking a major step in its Asia-Pacific expansion.

Genetic Signatures announces the upcoming departure of CEO Allison Rossiter, initiating a leadership transition as the company intensifies its focus on US market expansion.

Bioxyne Limited has secured a pioneering manufacturing and supply agreement to enter the emerging medicinal cannabis markets of Costa Rica and Panama, positioning itself as a first mover with promising revenue potential.

Mayne Pharma has rejected Cosette Pharmaceuticals’ notice to terminate their merger agreement, citing Cosette’s failure to meet obligations that led to regulatory approval issues. The dispute raises fresh uncertainty over the proposed acquisition’s future.

Algorae Pharmaceuticals has secured a $384,466 cash refund from the Australian Taxation Office, reinforcing its financial position to advance AI-driven drug discovery programs.

Algorae Pharmaceuticals has secured a key distribution agreement with global giant Dr. Reddy’s Laboratories to supply the chemotherapy drug Capecitabine in Australia, marking a significant step in its oncology commercialisation strategy.

Mayne Pharma’s acquisition by Cosette Pharmaceuticals faces a brief delay as FIRB extends its approval deadline, prompting a reschedule of the critical court hearing to November 23.

The Takeovers Panel has declared unacceptable circumstances in the Mayne Pharma acquisition after Cosette Pharmaceuticals changed its intentions to close the Salisbury manufacturing site, raising concerns over market transparency and regulatory approval.

The Takeovers Panel has declared unacceptable circumstances in the Mayne Pharma acquisition, ordering Cosette Pharmaceuticals to comply with conditions preventing closure of the Salisbury manufacturing site. This ruling highlights concerns over market transparency and the integrity of the takeover process.

Algorae Pharmaceuticals has launched a Loyalty Options Offer, allowing eligible shareholders to purchase options at a nominal price, aiming to reward loyalty and support future growth funding.

The FDA's removal of the black box warning on hormone replacement therapies marks a pivotal shift for Mayne Pharma, potentially unlocking new market opportunities and reshaping women’s health treatment.

Mayne Pharma has received notice of Cosette Pharmaceuticals' intention to appeal a court ruling in their acquisition dispute, potentially delaying the proposed takeover. The legal saga continues as key approvals and hearings loom.